Tanai Therapeutics
The computed 12-month bankruptcy probability of Tanai Therapeutics is 0.7% (low). The 2025 annual accounts show equity of €3.56M and a net result of €-2.49M. Its solvency ranks better than 95% of 84 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €3.56M |
| Net result | €-2.49M |
| Better than sector | 95% |
| Active | 2 yrs |
Mixed profile: strong on solvency, weaker on profitability.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 91.8% | 46.6% | |
| Net result | €-2.49M | €15k | |
| Equity | €3.56M | €86k | |
| Gross operating margin | €-528k | €44k | |
| Total assets | €3.87M | €251k |
Show 8 other metrics
| Fiscal year | 2025 |
|---|---|
| Deposit | verkort |
| Revenue | - |
| EBITDA | €-529k |
| Net profit | €-2.49M |
| Cash flow | €-443k |
| Staff costs | - |
| Income taxes | €-45k |
| Dividends | - |
| Total assets | €3.87M |
| Equity | €3.56M |
| Debt | €316k |
| of which ≤ 1y | €316k |
| of which > 1y | - |
| Working capital | €2.67M |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 9.47 |
| Quick ratio | 9.47 |
| Working capital ratio | 69.0% |
| Solvency | 91.8% |
| Debt / equity | 0.09 |
| Long-term debt ratio | - |
| Interest coverage | -97.37 |
| Gross margin | - |
| Net margin | - |
| ROA | -64.2% |
| ROE | -70.0% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (22 line items)
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €3.87M |
| Fixed assets | 21/28 | €884k |
| Intangible fixed assets | 21 | €850k |
| Tangible fixed assets | 22/27 | €34k |
| Current assets | 29/58 | €2.99M |
| Amounts receivable within one year | 40/41 | €72k |
| Cash & bank | 54/58 | €2.73M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €3.87M |
| Equity | 10/15 | €3.56M |
| Contributions / capital | 10/11 | €7.85M |
| Accumulated profits (losses) | 14 | €-4.29M |
| Amounts payable | 17/49 | €316k |
| Amounts payable within one year | 42/48 | €316k |
| Trade debts payable within one year | 44 | €316k |
| Income statement | ||
| Gross operating margin | 9900 | €-528k |
| Operating result | 9901 | €-2.57M |
| Financial income | 75 | €46k |
| Financial charges | 65 | €5k |
| Result before taxes | 9903 | €-2.53M |
| Income taxes | 67/77 | €-45k |
| Net result for the period | 9904 | €-2.49M |
| Result to be appropriated | 9905 | €-2.49M |
-
PROsVenture BVLegal entityDirector· perm. rep.: PROsVenture BVState Gazette act 25015391 (30-01-2025)Current17-12-2024 → present
| NACE primary | Speur- en ontwikkelingswerk op biotechnologisch gebied(72101) |
| Legal form | Public limited company(014) |
| Incorporation | 13-11-2023 |
| Status | Active |
| Postal code | 9051 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44062B0298/00V002 | Flanders | 2,297 m² | 1 · 810 m² | 13.1 m · 3 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
30-01-2025 2 directors appointed
- PROsVenture BV, Bestuurder
- PROsVenture BV, Dagelijks bestuur
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "PROsVenture BV",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": {
"kbo": "0698.880.149",
"name": "PROsVenture BV",
"address": "Twee Dreven 37, 9840 De Pinte",
"country": "BE",
"legal_form": "BV"
},
"statutory": "statutair",
"compensated": null,
"effective_date": "2024-12-17",
"evidence_quote": "De algemene vergadering beslist tot de benoeming van de PROsVenture BV, met zetel te Twee Dreven 37, 9840 De Pinte en met ondernemingsnummer 0698.880.149 (RPR Gent, afdeling Gent), vertegenwoordigd door Pieter Rottiers als bestuurder van de Vennootschap en met name \u0022CEO bestuurder\u0022 met ingang van 17",
"decharge_status": null,
"mandate_duration": {
"kind": "until_agm_year",
"value": "2030"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "delegation_dagelijks_bestuur_in",
"role": "dagelijks_bestuur",
"person": {
"rrn": null,
"name": "PROsVenture BV",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "successor_conditional",
"via_org": {
"kbo": "0698.880.149",
"name": "PROsVenture BV",
"address": "Twee Dreven 37, 9840 De Pinte",
"country": "BE",
"legal_form": "BV"
},
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "De raad van bestuur besluit om PROsVenture BV, met zetel te Twee Dreven 37. 9840 De Pinte en met ondernemingsnummer 0698.880.149 (RPR Gent, afdeling Gent), vast vertegenwoordigd door Pieter Rottiers, te benoemen als persoon belast met het dagelijks bestuur van de Vennootschap onder de opschortende v",
"decharge_status": null,
"mandate_duration": {
"kind": "until_date",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "decharge_granted",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Pieter Rottiers",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "De raad van bestuur beslist hierbij volmacht te geven aan Christoph Michiels, Tine Bassens, Elena Vromans en iedere medewerker van het kantoor Deloitte Legal - Lawyers BV, afzonderlijk handelend, met macht van indeplaatsstelling, voor de opstelling en de ondertekening van het formulier vereist voor ",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Luik",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2025-01-30",
"filing_date": "2025-01-17",
"act_kind_objet": "BENOEMING BESTUURDER"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2024-12-17",
"unanimous": true
},
{
"body": "raad_van_bestuur",
"date": "2024-12-17",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "1002.228.546",
"name_full": "Tanai Therapeutics",
"legal_form": "Naamloze vennootschap"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Tine Bassens",
"org_rep_person_name": null,
"person_role_at_subject": "bijzonder gevolmachtigde"
},
"co_filed_documents": [
"Bijlagen bij het Belgisch Staatsblad-30/01/2025 - Annexes du Moniteur belge"
],
"corrected_publication_numac": null
}12-07-2024 Capital increase of €2,000,000 to €7,850,000
- €5.850.000 → €7.850.000
- Inbreng in geld · Apport en numéraire
- 2 kapitaalbewegingen in deze akte
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 7850000.0,
"delta_eur": 2000000.0,
"before_eur": 5850000.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 2000000,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 1.0
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 2000000.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "warrant_issuance",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 872223,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": 872223,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTARISSEN",
"office_city": "Brussel",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2024-07-12",
"filing_date": "2024-07-10",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2024-06-28",
"unanimous": null,
"under_authorized_capital": true,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "1002.228.546",
"name_full": "Tanai Therapeutics",
"legal_form": "Naamloze vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"uitgifte van het proces-verbaal",
"twee volmachten",
"een verslag van het bestuursorgaan",
"een verslag van een bedrijfsrevisor",
"de geco\u00F6rdineerde tekst van statuten"
],
"shareholders_after": [],
"share_classes_after": []
}16-11-2023 Publication in the Belgian Official Gazette, Minor change
Technical details
{
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTARISSEN",
"office_city": "Brussel",
"is_associated": true
},
"act_meta": {
"language": "nl",
"pub_date": "2023-11-16",
"filing_date": "2023-11-13",
"act_kind_objet": "OPRICHTING"
},
"decision": {
"body": "notarieel_alleen",
"date": "2023-11-09",
"unanimous": null
},
"agm_change": null,
"detected_kind": "oprichting",
"other_address": null,
"mandate_renewal": null,
"subject_company": {
"kbo": "1002.228.546",
"name_full": "Tanai Therapeutics",
"legal_form": "NV"
},
"accounts_deposit": null,
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null
},
"co_filed_documents": [
"een uitgifte van de akte",
"vier volmachten",
"de geco\u00F6rdineerde tekst van statuten",
"een verslag van de bedrijfsrevisor",
"een verslag van de oprichter opgesteld overeenkomstig artikel 7:7, \u00A71 van het Wetboek van vennootschappen en verenigingen"
],
"fiscal_year_change": {
"new_end_mm_dd": "31",
"old_end_mm_dd": null,
"new_start_mm_dd": "01",
"old_start_mm_dd": null,
"first_full_new_year": 2025,
"transition_period_end": "2024-12-31"
},
"liquidation_closure": null,
"officer_designation": null,
"special_procuration": null,
"is_volet_a_only_stub": false,
"vakbekwaamheid_change": null,
"should_reroute_to_category": null,
"single_shareholder_declaration": null
}| Legal nameNL | Tanai Therapeutics |